It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The relative abundance of Wnt receptors plays a crucial role in controlling Wnt signaling in tissue homeostasis and human disease. While the ubiquitin ligases that ubiquitylate Wnt receptors are well-characterized, the deubiquitylase that reverses these reactions remains unclear. Herein, we identify USP46, UAF1, and WDR20 (USP46 complex) as positive regulators of Wnt signaling in cultured human cells. We find that the USP46 complex is similarly required for Wnt signaling in Xenopus and zebrafish embryos. We demonstrate that Wnt signaling promotes the association between the USP46 complex and cell surface Wnt coreceptor, LRP6. Knockdown of USP46 decreases steady-state levels of LRP6 and increases the level of ubiquitylated LRP6. In contrast, overexpression of the USP46 complex blocks ubiquitylation of LRP6 by the ubiquitin ligases RNF43 and ZNFR3. Size exclusion chromatography studies suggest that the size of the USP46 cytoplasmic complex increases upon Wnt stimulation. Finally, we show that USP46 is essential for Wnt-dependent intestinal organoid viability, likely via its role in LRP6 receptor homeostasis. We propose a model in which the USP46 complex increases the steady-state level of cell surface LRP6 and facilitates the assembly of LRP6 into signalosomes via a pruning mechanism that removes sterically hindering ubiquitin chains.
Wnt receptors are controlled by their ubiquitin-mediated proteolysis. The authors show that the USP46 deubiquitylase complex potentiates Wnt signaling in human cells, Xenopus, and zebrafish by inhibiting cell surface LRP6 degradation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Vanderbilt University, Department of Cell & Developmental Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
2 Geisel School of Medicine at Dartmouth College, Department of Molecular and Systems Biology and the Dartmouth Cancer Center, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404)
3 Vanderbilt University, Department of Cell & Developmental Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); University of Maryland School of Medicine, Department of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
4 Georgetown University, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)
5 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
6 Vanderbilt University, Department of Cell & Developmental Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
7 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.511215.3) (ISNI:0000 0004 0455 2953); University of California San Francisco, Department of Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
8 Vanderbilt University, Department of Cell & Developmental Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); STEMCELL Technologies, Vancouver, Canada (GRID:grid.37213.34) (ISNI:0000 0004 0640 9958)
9 National Cancer Institute, National Institutes of Health, Laboratory of Cellular and Molecular Biology, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
10 Stanford University School of Medicine, Departments of Biochemistry, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
11 University of Maryland School of Medicine, Department of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
12 Vanderbilt University, Department of Cell & Developmental Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)